Loading the section…
We use cookies to keep the site working and to understand which materials are useful. Which cookies · Data processing policy.
MD Medical Group IPJSC (MDMG): profit is backed by cash, cash flow to profit 0.87×. Dividends are sustainable, yield 3.6%. The debt load is low, net debt / EBITDA −0.20×. Data as of 23/10/2026.
Answers to 3 of 4 questions · The analysis is assembled by a program from the data on this page
P/E is now 8.81×, above its own median of 8.01× across 5 annual reports: on this multiple the share is priced higher than it usually is.
This compares the share with its own history; it is not a recommendation or a forecast.
This section reads the financial statements only; it does not assess market, industry or sanctions risks.
Does the company pay dividends regularly and can it afford the payout
Payouts are regular: the last one was RUB 47.00. The history holds 5 payouts in total. The payout ratio is 60.5% of the period's profit. The dividend yield at the last closing price is 3.6%. The sector median is 4.8%: the security's yield is below it.
P/E · IFRS · Price as of 23/10/2026; ratios from the 2025 annual report
Based on the current price and the 2025 annual report, P/E is 8.81×. In earlier years it ranged from 6.72× to 10.19×, with a median of 8.01×; observations: 5. That is above its own median.
By report year — at the price on the day each year's report came out. The minimum, maximum, median and number of observations are taken over the earlier years: the last year in this list is not part of them
P/E
Observations with a similar valuation: 5. The price was higher by the next annual report in this many cases: 3. The median price change was 14.1%, ranging from −17.3% to 89.6%.
A similar valuation means P/E within a quarter of the current value. Each year's price is taken the following spring, once the annual report is known; the price change runs between those dates of adjacent years and excludes dividends. The share count used is the current one. This describes the past and is not a forecast.
Dividends are sustainable, yield 3.6%. The last payout was RUB 47.00 per share.
The debt load is low, net debt / EBITDA −0.20×.
Based on the current price and the 2025 annual report, P/E is 8.81×. In earlier years it ranged from 6.72× to 10.19×, with a median of 8.01×; observations: 5. That is above its own median.
There is no forecast here: this page does not predict the price. It shows what happened after a similar valuation in the past. Observations with a similar valuation: 5. The price was higher by the next annual report in this many cases: 3. The median price change was 14.1%, ranging from −17.3% to 89.6%. A similar valuation means P/E within a quarter of the current value. Each year's price is taken the following spring, once the annual report is known; the price change runs between those dates of adjacent years and excludes dividends. The share count used is the current one. This describes the past and is not a forecast.
The company's statements do not hold enough data for these questions yet:
What date the figures on this page are as of
The analysis is built on the issuer's published financial statements and disclosures. It is information, not investment advice.
Data as of 23/10/2026
How large the company's debt is relative to its earnings
The company holds more cash than debt: the ratio of net debt to EBITDA is negative and equals −0.20×. Over the year the debt load rose; the change is +0.35×. The sector median is 1.44×: the company's debt load is below it.
Data as of 23/10/2026
Is the company's profit backed by real cash
The ratio of free cash flow to net income is 0.87×: what was earned did arrive as cash. In money terms, that is RUB 9.63 bn of cash flow against profit of RUB 11.04 bn.
Data as of 23/10/2026